Kang WY - Search Results

1

Follistatin-like 1 promotes osteoclast formation via RANKL-mediated NF-κB activation and M-CSF-induced precursor proliferation.

Kim HJ, Kang WY, Seong SJ, Kim SY, Lim MS, Yoon YR. Kim HJ, et al. Among authors: kang wy. Cell Signal. 2016 Sep;28(9):1137-1144. doi: 10.1016/j.cellsig.2016.05.018. Epub 2016 May 24. Cell Signal. 2016. PMID: 27234130

2

G Protein-Coupled Receptor 120 Signaling Negatively Regulates Osteoclast Differentiation, Survival, and Function.

Kim HJ, Yoon HJ, Kim BK, Kang WY, Seong SJ, Lim MS, Kim SY, Yoon YR. Kim HJ, et al. Among authors: kang wy. J Cell Physiol. 2016 Apr;231(4):844-51. doi: 10.1002/jcp.25133. Epub 2015 Sep 1. J Cell Physiol. 2016. PMID: 26280807

3

Deficiency of Lipocalin-2 Promotes Proliferation and Differentiation of Osteoclast Precursors via Regulation of c-Fms Expression and Nuclear Factor-kappa B Activation.

Kim HJ, Ohk B, Kang WY, Seong SJ, Suk K, Lim MS, Kim SY, Yoon YR. Kim HJ, et al. Among authors: kang wy. J Bone Metab. 2016 Feb;23(1):8-15. doi: 10.11005/jbm.2016.23.1.8. Epub 2016 Feb 29. J Bone Metab. 2016. PMID: 26981515 Free PMC article.

4

Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects.

Seong SJ, Lim MS, Lee J, Ohk B, Gwon MR, Kim BK, Kim HJ, Yang DH, Lee HW, Kang WY, Yoon YR. Seong SJ, et al. Among authors: kang wy. Clin Drug Investig. 2016 Aug;36(8):613-23. doi: 10.1007/s40261-016-0406-y. Clin Drug Investig. 2016. PMID: 27206575

5

Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.

Kang WY, Kim EH, Seong SJ, Gwon MR, Yang DH, Kim HJ, Lim MS, Lee HW, Yoon YR. Kang WY, et al. Int J Clin Pharmacol Ther. 2016 Dec;54(12):992-1003. doi: 10.5414/CP202615. Int J Clin Pharmacol Ther. 2016. PMID: 27668695 Clinical Trial.

6

Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.

Kim HJ, Ohk B, Yoon HJ, Kang WY, Seong SJ, Kim SY, Yoon YR. Kim HJ, et al. Among authors: kang wy. Cell Signal. 2017 Jan;29:226-232. doi: 10.1016/j.cellsig.2016.11.007. Epub 2016 Nov 9. Cell Signal. 2017. PMID: 27836739

7

G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.

Park JW, Yoon HJ, Kang WY, Cho S, Seong SJ, Lee HW, Yoon YR, Kim HJ. Park JW, et al. Among authors: kang wy. J Cell Physiol. 2018 Feb;233(2):1481-1489. doi: 10.1002/jcp.26035. Epub 2017 Jul 4. J Cell Physiol. 2018. PMID: 28574596

8

Neuromedin B and its receptor silencing suppresses osteoclast generation by modulating precursor proliferation via M-CSF/c-Fms/D-type cyclins.

Yeo CE, Kang WY, Seong SJ, Cho S, Lee HW, Yoon YR, Kim HJ. Yeo CE, et al. Among authors: kang wy. Exp Cell Res. 2017 Oct 1;359(1):112-119. doi: 10.1016/j.yexcr.2017.08.003. Epub 2017 Aug 3. Exp Cell Res. 2017. PMID: 28780306

9

Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate.

Lee HW, Seong SJ, Ohk B, Kang WY, Gwon MR, Kim BK, Kim HJ, Yoon YR. Lee HW, et al. Among authors: kang wy. Drug Des Devel Ther. 2017 Sep 13;11:2719-2725. doi: 10.2147/DDDT.S142339. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29066863 Free PMC article. Clinical Trial.

10

Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects .

Kang WY, Seong SJ, Ohk B, Gwon MR, Kim BK, Na S, Kim HJ, Yoon YR, Lee HW. Kang WY, et al. Int J Clin Pharmacol Ther. 2018 Jan;56(1):43-52. doi: 10.5414/CP203026. Int J Clin Pharmacol Ther. 2018. PMID: 29162214 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

230 results

Search Page

Filters